Kiniksa Pharmaceuticals International plc Class A Ordinary Shares (KNSA)

FairStock Score: 51/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a patient value investor, and Kiniksa is a classic specialty-pharma turnaround. In fiscal 2024, the company lost $43.2 million on $423.2 million of revenue. By fiscal 2025, revenue rose to $677.6 million and net income swung to $59.0 million, or $0.75 diluted EPS. The first fiscal quarter of 2026 showed more momentum: revenue of $214.3 million, net income of $22.6 million, and diluted EPS of $0.27, versus $137.8 million, $8.5 million, and $0.11 in the first fiscal quarter of 2025. That is real operating leverage.

In plain English: Kiniksa is a small drug company that sells ARCALYST for recurrent pericarditis and cardiac sarcoidosis and is developing another medicine. The business has grown quickly and recently became profitable, with little debt and positive cash flow. But at $78.53 a share, the price looks high compared with what the company earns and owns, so much future growth is already priced in.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer